Latest News and Press Releases

Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed medical journal Gynecologic Oncology Phase 3 OVATION 3 Study in progress ...

$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants LAWRENCEVILLE, N.J., May 28, 2025 (GLOBE NEWSWIRE)...

Presentation at ESMO will follow oral 2025 ASCO Annual Meeting presentation highlighting unprecedented survival data from Phase 2 OVATION 2 Study of IMNN-001 Simultaneously publication in leading...

$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants LAWRENCEVILLE, N.J., May 23, 2025 (GLOBE NEWSWIRE)...

Data show continuous clinically significant improvement, with median 13-month and 3-month increases in overall and progression-free survival, respectively, in treatment group Women treated with...

LAWRENCEVILLE, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has...

Company’s PlaCCine® technology platform demonstrates better durability and other advantages compared to mRNA vaccines Results further validate PlaCCine as a novel vaccine platform with potential...

First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation...

Company currently initiating additional trial sites and working with study investigators to enroll participants IMNN-001 is the first and only immunotherapy to show meaningful overall survival...

Data from OVATION 2 trial will also be reviewed in an oral presentation at ASCO Annual Meeting on June 3, 2025 LAWRENCEVILLE, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a...